Abstract: The biopharmaceutical industry has been globally recognized as a high-tech sector. With the burgeoning development of the biopharmaceutical industry in China, an intriguing question is to what extent the critical equipment, such as bioreactors, are on a global level and whether they will remain competitive looking forward. This study constructs a two-stage funnel screening model for key core technologies. In the first stage, the social network analysis method is used to identify the core technology fields of bioreactors. In the second stage, from the perspective of the innovation chain, a system of indicators is established to determine the importance of technologies, thus filtering out key core technologies within the industry. Based on the results of key core technology screening, a "quantity of patents-quality of patents" technology gap measurement model is constructed to assess national gaps. Using nearly ten years of global patent data in the bioreactor industry as a sample for verification and analysis, the study finds that there are 315 key core technologies in the bioreactor industry, mainly concentrated in the fields of enzymology or microbiological devices (C12M) and treatment of water, wastewater, sewage, or sludge (C02F); the United States holds an absolute advantage in the field of bioreactors; China is at a disadvantage in five technological fields, presenting a significant risk of being "strangled" technologically. Therefore, China needs to invest in research and development for bioreactor technologies and tackle key issues to drive sustainable development in this industry.

摘要： 生物医药行业已被全球公认为高技术行业。中国生物医药行业方兴未艾，其中作为关键装备的生物反应器在全球究竟处于何等水平，面向未来是否有竞争力是一个值得探究的问题。研究构建关键核心技术两阶段漏斗式筛选模型，一阶段采用社会网络分析法识别生物反应器核心技术领域，二阶段从创新链视角出发构建技术关键程度判断指标体系，从而筛选得到行业内关键核心技术；在关键核心技术筛选结果基础上构建“专利数量-专利质量”技术差距测度模型以研判国别差距。以全球生物反应器行业近十年专利数据为样本进行验证分析，研究发现：生物反应器行业内拥有关键核心技术315项，并主要集中于酶学或微生物学装置（C12M）及水、废水、污水或污泥的处理（C02F）领域；美国在生物反应器领域占据着绝对优势；中国在五个技术领域处于劣势，“被卡脖子”风险较大。因此，中国需要对生物反应器技术进行研发投入和攻关，以驱动该产业可持续发展。